Previous 10 | Next 10 |
home / stock / jnj / jnj articles
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (ARCA:IYH), ...
Wednesday, Johnson & Johnson (NYSE:JNJ) announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of sel...
The mass retirement of the boomer generation has been anticipated as one of the most impactful economic events of the 21st century. Economists are ...
A group of cancer victims has reportedly filed a lawsuit against Johnson & Johnson (NYSE:JNJ), accusing the healthcare gian...
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Vanguard Health Care ETF (ARCA:VHT), a p...
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze compani...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused o...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
News, Short Squeeze, Breakout and More Instantly...
Assa Abloy AB ADR (ASAZY) is expected to report for Q2 2024 First Horizon Corporation (FHN) is expected to report $0.37 for Q2 2024 Community Trust Bancorp Inc. (CTBI) is expected to report $1.03 for Q2 2024 Cohen & Steers Inc (CNS) is expected to report for Q2 2024 First Indu...
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on Aug...
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (&...